AXL and renal cell adenocarcinoma: Cabozantinib is a multitarget RTK inhibitor that inhibits several RTKs, including MET, RET, VEGFR-1-3, KIT, FLT-3, TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL, and it has been clinically approved for the treatment of medullary thyroid cancer (MTC) (33), renal cell cancer (RCC) (34), and hepatocellular carcinoma (HCC) (35).